▼ Olumiant® (baricitinib)

Olumiant® (baricitinib) is a once-daily tablet indicated for the treatment of moderate to severe active Rheumatoid Arthritis in adult patients.
Download or click these links to find out more information about baricitinib:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. This information is brought to you by Lilly, the manufacturers of this medicine.

Reporting side effects

If you experience side effects, talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the Patient Information Leaflet. Any side effects from your medication can be reported at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Any side effects or complaints regarding Lilly Products can be reported directly to Lilly UK calling 01256 315 000

▼ Taltz® (ixekizumab)

Taltz (ixekizumab) is a biologic treatment for adults with moderate-to-severe plaque psoriasis. Taltz is also used for the treatment of adults with active psoriatic arthritis.
Download or click these links below to find out more information about ixekizumab:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. This information is brought to you by Lilly, the manufacturers of this medicine.

Reporting an adverse event:

Please do not use this website to report side effects from or complaints about your medication. If you experience side effects talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. Any side effects from your medication can be reported at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Any side effects or complaints regarding Lilly Products can be reported directly to Lilly UK calling 01256 315 000

Forsteo® (teriparatide)

Forsteo (teriparatide) is an anabolic treatment used for the treatment of osteoporosis (a disease that makes bones fragile) in the following groups:

Download or click these links below to find out more information about teriparatide:

Reporting an adverse event:

Please do not use this website to report side effects from or complaints about your medication. If you experience side effects talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. Any side effects from your medication can be reported at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Any side effects or complaints regarding Lilly Products can be reported directly to Lilly UK calling 01256 315 000 PP-LR-GB-0245 October 2018